SuperworthSupernus Pharmaceuticals profit margin SUPN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2014.
- Net margin, 12 months
- −13.2%
- Operating margin, 12 months
- −15.7%
- Net margin on a year earlier
- −22.9 pts
- Peer median
- 11.1%
Over the twelve months to Jun 30, 2026, Supernus Pharmaceuticals kept −13.2% of its revenue as net profit, with an operating margin of −15.7% and a gross margin of 88.1%.
Five years earlier its net margin was 17.5%.
The median for 10 large drugmakers of a similar size is 11.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −5.4% | −8.7% | 89.6% |
| FY2024 | 11.2% | 12.3% | 88.2% |
| FY2023 | 0.2% | −0.9% | 86.2% |
| FY2022 | 9.1% | 6.9% | 86.9% |
| FY2021 | 9.2% | 14.8% | 87.1% |
| FY2020 | 24.4% | 33.4% | 89.9% |
| FY2019 | 28.8% | 37.8% | 95.8% |
| FY2018 | 27.1% | 35.3% | 96.2% |
| FY2017 | 19.0% | 32.9% | 95.0% |
| FY2016 | 42.4% | 25.2% | 94.4% |
| FY2015 | 9.5% | 14.1% | 94.3% |
| FY2014 | −11.8% | −5.7% | 93.8% |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −13.2% | −22.9 pts | −15.7% | |
| Q1 FY26 | −3.7% | −13.0 pts | −7.8% | |
| Q4 FY25 | −5.4% | −16.5 pts | −8.7% | |
| Q3 FY25 | −2.8% | −12.0 pts | −5.4% | |
| Q2 FY25 | 9.7% | +8.9 pts | 9.6% | |
| Q1 FY25 | 9.3% | +11.9 pts | 11.2% | |
| Q4 FY24 | 11.2% | +10.9 pts | 12.3% | |
| Q3 FY24 | 9.2% | +5.0 pts | 9.1% | |
| Q2 FY24 | 0.8% | −6.0 pts | 4.2% | |
| Q1 FY24 | −2.6% | −10.4 pts | −2.3% | |
| Q4 FY23 | 0.2% | −8.9 pts | −0.9% | |
| Q3 FY23 | 4.2% | −1.5 pts | 4.9% |
Against its peers
Companies in Drug Manufacturers - General nearest Supernus Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| SUPNSupernus Pharmaceuticals | −13.2% |
| PBHPrestige Consumer Healthcare | 15.6% |
| HRMYHarmony Biosciences | 18.9% |
| NRIXNurix Therapeutics | 42.0% |
| ANIPANI Pharmaceuticals | 11.1% |
| PAHCPhibro Animal Health | 6.6% |
| OGNOrganon | 3.4% |
| LQDALiquidia | 30.7% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| ARQTArcutis Biotherapeutics | 6.1% |
| Peer median | 11.1% |
Where Supernus Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Supernus Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.